Astute Medical, Inc.
$104.6K 0 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Pylant Medical
Pylant Medical reported $104,677.64 across General Payments, Research, and Ownership to 1,589 physicians and teaching hospitals across 1,589 transactions.
- $104.7K Below-median payer
- All-tracks total
- 1,589 Top quartile volume
- Transactions
- 1,589 Top quartile reach
- Recipients
- +$35.0K
- General Payments vs PY2023
Pylant Medical reported $104,677.64 across all CMS Open Payments tracks (General + Research + Ownership) to 1,589 physicians and teaching hospitals in Program Year 2024 - ranking #1171 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $104,677.64, averaging $65.88 per recipient.
Pylant Medical's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
20/100
Total payments
F
11/100
Transaction volume
F
22/100
Physician reach
F
22/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer pylant-medical Pylant Medical
$104.7K · #1171/1,925 · 0.0% industry · PY2024
- TOT $104.7K
- RANK #1171
- SHARE 0.0%
- TXN 1,589
- RCP 1,589
- CAT 2
- GEN $104.7K
- ΔGEN +$35.0K
- TOP1 1.6%
- PY 2024
Volume peers
Nearest volume peer: Astute Medical, Inc. ($104.6K)
Pylant Medical sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Pylant Medical's CMS-reported General Payments increased by $35.0K (+50.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: PYLANT MEDICALPY2023: PYLANT MEDICALPY2024: Pylant Medical. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $69,680.48
- PY2024
- $104,677.64
What the Data Shows for Pylant Medical
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Pylant Medical that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 2-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $84.4K, accounting for 80.6% of this company's General Payments and 1,498 transactions.
General Payment Breakdown by Type
"Food and Beverage" leads Pylant Medical's 2-category general-payment breakdown at $84.4K, 80.6% of the reported total.
How Pylant Medical divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $84.4K | 1,498 | 80.6% |
| Travel and Lodging | $20.3K | 91 | 19.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $6,186.29 (5.9%) of $104,677.64 in this company's General Payments records across 768 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Pylant Medical
The five named recipients with the highest reported General Payments from this company
- 1
William Bowlin
$1,624.99 across 9 reported transactions
- 2
Ishvinder Grewal
$1,180.29 across 11 reported transactions
- 3
Peter Derman
$1,176.56 across 7 reported transactions
- 4
Augustus Rush
$1,169.59 across 4 reported transactions
- 5
Neil Patel
$1,034.86 across 4 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Pylant Medical ranks #1171 of 1,925 by total payments (bottom 39% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,782 of 1,838 by HHI (bottom 3% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Benco Dental Supply Co. : $148.4K total payments, HHI 43
- Premier Dental Products Company : $182.7K total payments, HHI 43
- DePuy Synthes Sales Inc. : $2.4M total payments, HHI 42
- IBSA Pharma Inc. : $247.0K total payments, HHI 42
- Supernus Pharmaceuticals, Inc. : $4.4M total payments, HHI 42
- Ethicon US, LLC : $1.6M total payments, HHI 41
- Pylant Medical (this company) : $104.7K total payments, HHI 40
- Teva Pharmaceuticals USA, Inc. : $13.9M total payments, HHI 40
- American Orthodontics Corporation : $374.7K total payments, HHI 38
- Impel Pharmaceuticals LLC : $15.8K total payments, HHI 36
- Ultradent Products Inc : $1.8M total payments, HHI 36
- OWP Pharmaceuticals, Inc. : $7.8K total payments, HHI 35
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Pylant Medical's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Pylant Medical.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Pylant Medical.
Showing 6 of 1,924 companies with CMS-reported payment data.
Coltene Whaledent Inc.
$105.1K 222 recipients
Compare payment profiles
OrthoPediatrics Canada ULC
$104.0K 5 recipients
Compare payment profiles
HMU Consumables, LLC
$103.7K 0 recipients
Compare payment profiles
Think Surgical, Inc.
$103.4K 207 recipients
Compare payment profiles
Halozyme Inc
$103.3K 326 recipients
Compare payment profiles
Put this to use
Pylant Medical ranks #1171 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Pylant Medical. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.